MatchTx provides a SaaS solution that helps researchers, oncologists and clinical trial managers identify the full set of biomarkers that collectively predict the outcome of cancer patients to treatments. Patent-pending algorithms classify millions of combinations of genomic and clinical data to find the full set predictive biomarkers (Deep Genetic Signatures™) from reference data sets. The Signatures are used to identify the previous tumors ‘most like my patient’s cancer’ to match therapeutics based on real patient outcomes, not just population averages.